statnews.com·May 22, 2026
Merck's antibody-drug conjugate, sacituzumab tirumotecan, has shown significant efficacy in a Phase 3 lung cancer study when combined with Keytruda, outperforming Keytruda alone. Additionally, the NIH faces leadership changes, and Retro Biosciences, a longevity startup backed by Sam Altman, has secured more funding.
Merck's successful Phase 3 trial of sacituzumab tirumotecan with Keytruda in lung cancer patients indicates a promising advancement in precision medicine through antibody-drug conjugates. This could signal a valuable investment or partnership opportunity for stakeholders in the biotech and pharmaceutical sectors, particularly those focusing on oncology treatments.